Search research articles
Contact Us
Filters
Showing results (81-90 of 191) with videos related to
Page
of 20
Sort By:
Journal for Immunotherapy of Cancer
|
July 27, 2024
Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort
Sandip P Patel, Megan Othus, Young Kwang Chae, et al.
Journal for Immunotherapy of Cancer
|
November 7, 2023
Effect of CD4+ T cell count on treatment-emergent adverse events among patients with and without HIV receiving immunotherapy for advanced cancer
Thomas A Odeny, Kathryn Lurain, Julius Strauss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 14, 2022
Combined MEK/PD-L1 Inhibition Alters Peripheral Cytokines and Lymphocyte Populations Correlating with Improved Clinical Outcomes in Advanced Biliary Tract Cancer
Amanda N Ruggieri, Mark Yarchoan, Subir Goyal, et al.
Journal for Immunotherapy of Cancer
|
October 21, 2025
Multicenter phase II trial of ipilimumab and nivolumab in metastatic or unresectable perivascular epithelioid cell tumor (PEComa): a substudy of <i>D</i>ual <i>A</i>nti-CTLA-4 and Anti-PD-1 blockade in <i>R</i>are <i>T</i>umors (DART) SWOG S1609 (Cohort 38)
Sandip P Patel, Megan Othus, Young K Chae, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 26, 2023
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in Patients with Gestational Trophoblastic Neoplasia
Sandip P Patel, Megan Othus, Young Kwang Chae, et al.
Journal for Immunotherapy of Cancer
|
March 10, 2022
Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors
Osama E Rahma, Kevin Tyan, Anita Giobbie-Hurder, et al.
JAMA Network Open
|
February 27, 2020
Use of Magnetic Resonance Imaging to Identify Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis
Ananta Subedi, Sandra G Williams, Lawrence Yao, et al.
Open Forum Infectious Diseases
|
April 29, 2024
Exacerbation of CMV and Nontuberculous Mycobacterial Infections Following PD-1 Blockade for HIV-Associated Kaposi Sarcoma
Ifeanyichukwu U Anidi, Shunsuke Sakai, Kelsie Brooks, et al.
Cancer
|
April 21, 2021
A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: High-grade neuroendocrine neoplasm cohort
Sandip Pravin Patel, Edward Mayerson, Young Kwang Chae, et al.
Genome Medicine
|
January 4, 2024
Using multi-scale genomics to associate poorly annotated genes with rare diseases
Christina Canavati, Dana Sherill-Rofe, Lara Kamal, et al.
Page
of 20
Search research articles
Search
Showing results (81-90 of 191) with videos related to
Sort By:
Page
of 20
Journal for Immunotherapy of Cancer
|
July 27, 2024
Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort
Sandip P Patel, Megan Othus, Young Kwang Chae, et al.
Journal for Immunotherapy of Cancer
|
November 7, 2023
Effect of CD4+ T cell count on treatment-emergent adverse events among patients with and without HIV receiving immunotherapy for advanced cancer
Thomas A Odeny, Kathryn Lurain, Julius Strauss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 14, 2022
Combined MEK/PD-L1 Inhibition Alters Peripheral Cytokines and Lymphocyte Populations Correlating with Improved Clinical Outcomes in Advanced Biliary Tract Cancer
Amanda N Ruggieri, Mark Yarchoan, Subir Goyal, et al.
Journal for Immunotherapy of Cancer
|
October 21, 2025
Multicenter phase II trial of ipilimumab and nivolumab in metastatic or unresectable perivascular epithelioid cell tumor (PEComa): a substudy of <i>D</i>ual <i>A</i>nti-CTLA-4 and Anti-PD-1 blockade in <i>R</i>are <i>T</i>umors (DART) SWOG S1609 (Cohort 38)
Sandip P Patel, Megan Othus, Young K Chae, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 26, 2023
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in Patients with Gestational Trophoblastic Neoplasia
Sandip P Patel, Megan Othus, Young Kwang Chae, et al.
Journal for Immunotherapy of Cancer
|
March 10, 2022
Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors
Osama E Rahma, Kevin Tyan, Anita Giobbie-Hurder, et al.
JAMA Network Open
|
February 27, 2020
Use of Magnetic Resonance Imaging to Identify Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis
Ananta Subedi, Sandra G Williams, Lawrence Yao, et al.
Open Forum Infectious Diseases
|
April 29, 2024
Exacerbation of CMV and Nontuberculous Mycobacterial Infections Following PD-1 Blockade for HIV-Associated Kaposi Sarcoma
Ifeanyichukwu U Anidi, Shunsuke Sakai, Kelsie Brooks, et al.
Cancer
|
April 21, 2021
A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: High-grade neuroendocrine neoplasm cohort
Sandip Pravin Patel, Edward Mayerson, Young Kwang Chae, et al.
Genome Medicine
|
January 4, 2024
Using multi-scale genomics to associate poorly annotated genes with rare diseases
Christina Canavati, Dana Sherill-Rofe, Lara Kamal, et al.
Page
of 20